Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial

Authors:

Abstract
No abstract available

This publication has 30 references indexed in Scilit: